• Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine and methotrexate. (medscimonit.com)
  • Twenty-three patients experienced acute GVHD and 17 developed chronic GVHD. (medscimonit.com)
  • Graft-versus-host disease (GvHD) is a syndrome, characterized by inflammation in different organs. (wikipedia.org)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants. (wikipedia.org)
  • The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GvHD. (wikipedia.org)
  • GvHD occurs when the donor's immune system's white blood cells reject the recipient. (wikipedia.org)
  • GvHD can also occur after a blood transfusion, known as Transfusion-associated graft-versus-host disease or TA-GvHD if the blood products used have not been gamma irradiated or treated with an approved leukocyte reduction system. (wikipedia.org)
  • Mucosal damage to the vagina can result in severe pain and scarring, and appears in both acute and chronic GvHD. (wikipedia.org)
  • About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. (wikipedia.org)
  • Vascular injury has been seen in patients with acute graft versus host disease (GVHD) in the skin. (nih.gov)
  • We aimed to see whether vascular injury mediated by cytotoxic T lymphocytes and microvessel loss arises in patients with chronic GVHD. (nih.gov)
  • We investigated eight patients with acute GVHD and ten with chronic GVHD for signs of endothelial injury and microvessel loss by measurement of von Willebrand factor (vWF) in plasma and blood vessel density in biopsy samples taken from lesional skin. (nih.gov)
  • Perivascular CD8 T cell infiltrates in skin correlated with vWF plasma concentrations in patients with GVHD (p=0.01), and activated cytotoxic T lymphocytes and endothelial injury were present in these same samples. (nih.gov)
  • Substantial blood vessel loss may lead to impaired blood perfusion and tissue fibrosis, the hallmark lesion of chronic GVHD. (nih.gov)
  • Thus, prophylactic transfusion of donor T-cells has been included in many protocols, despite the increased risk for acute GvHD ( Kolb, 2008 ). (frontiersin.org)
  • Eight patients from the first NGFR-HSV-TK-studies developed acute ( n = 6) or chronic GvHD ( n = 2), which resolved after treatment with GCV alone in seven of eight patients. (frontiersin.org)
  • The inclusion of ATG resulted in a significantly lower rate of chronic GVHD after allogeneic transplantation than the rate without ATG. (bmj.com)
  • The survival rate was similar in the two groups, but the rate of a composite end point of chronic GVHD-free survival and relapse-free survival was higher with ATG. (bmj.com)
  • The plain English version would read: "In this two year, open-label trial, our company's antihuman T-lymphocyte immune globulin (ATG) halved the rate of chronic graft-versus-host disease (GVHD) in people who had previously undergone allogeneic haematopoietic stem-cell transplantation, but made no difference to mortality. (bmj.com)
  • My principle research interests are in the prevention and therapy of graft-versus-host disease (GVHD) and in the use of graft-versus-leukemia to eradicate blood disorders. (harvard.edu)
  • We have a series of clinical trials available to evaluate several different strategies to prevent GVHD, such as T cell depletion and the use of novel immunosuppressive agents. (harvard.edu)
  • The incidence of grade II-IV acute and chronic graft versus host disease (GvHD) was 23.6% and 12.9% respectively. (nih.gov)
  • Graft versus host disease (GVHD), a severe immunogenic complication of allogeneic hematopoietic stem cell transplantation (HSCT), represents the most frequent cause of transplant-related mortality (TRM). (hindawi.com)
  • Graft versus host disease (GVHD) represents the most frequent cause of TRM. (hindawi.com)
  • Shortly before graft infusion, GVHD prophylaxis (immunosuppression) is started. (hindawi.com)
  • The histocompatibility differences between the donor and the recipient, the presence of donor's immunocompetent cells, and the inability of the recipient to reject these cells were defined as the basic pathogenic prerequisites for GVHD development by Billingham in 1966 [ 10 ]. (hindawi.com)
  • Cytotoxic T lymphocytes were determined as the cellular effectors of GVHD, and the key role of antigen-presenting cells (APCs) in T-lymphocyte activation was established during the following years [ 11 , 12 ]. (hindawi.com)
  • Graft-versus-host disease (GVHD) is a complication that occurs following allo-HSCT and is a major driver of posttransplant morbidity and mortality [ 2 ]. (biomedcentral.com)
  • Watch Dr. Sandeep Jain's presentation at the GVHD patient summit about Chronic Graft-versus-Host Disease in the eyes. (uillinois.edu)
  • This article is a summary of the European Society for Blood and Marrow Transplantation (EBMT) webinar entitled 'Pathophysiology of acute and chronic GvHD, novel therapeutic strategies in the preclinical phase' delivered by Ernst Holler on May 5th, 2020. (gvhdhub.com)
  • The restoration of hematopoiesis together with the donor's immune system can lead to a major immune reaction, graft- versus -host disease (GvHD). (gvhdhub.com)
  • Key target indications for the platforms include Graft versus Host Disease (GvHD), Systemic lupus erythematosus (SLE), Systemic Sclerosis (SSc) and high-risk tibial fractures. (lifecarenews.in)
  • Graft-versus-host disease (GVHD) is a life-threatening complication that can occur after certain stem cell or bone marrow transplants . (medlineplus.gov)
  • GVHD may occur after a bone marrow, or stem cell, transplant in which someone receives bone marrow tissue or cells from a donor. (medlineplus.gov)
  • GVHD does not occur when people receive their own cells. (medlineplus.gov)
  • There are two types of GVHD: acute and chronic. (medlineplus.gov)
  • Symptoms in both acute and chronic GVHD range from mild to severe. (medlineplus.gov)
  • Chronic GVHD usually starts more than 3 months after a transplant, and can last a lifetime. (medlineplus.gov)
  • Many cases of acute or chronic GVHD can be treated successfully. (medlineplus.gov)
  • The allogeneic HSCT was the most frequently performed (57.14%) and the most used source of Hematopoietic progenitor cells (HPC) was the peripheral blood (54.29%) and 5.71% of these patients developed the Graft versus Host Disease (GVHD), of which one was affected by acute GVHD and another by chronic GVHD. (bvsalud.org)
  • HSCT patients are presumed immunocompetent if they are at least 24 months post-HSCT, are not receiving immunosuppressive therapy, and do not have graft- versus-host disease (GVHD). (cdc.gov)
  • In the clinical setting, graft-versus-host disease is divided into acute and chronic forms, and scored or graded on the basis of the tissue affected and the severity of the reaction. (wikipedia.org)
  • In the classical sense, acute graft-versus-host disease is characterized by selective damage to the liver, skin (rash), mucosa, and the gastrointestinal tract. (wikipedia.org)
  • Newer research indicates that other graft-versus-host disease target organs include the immune system (the hematopoietic system, e.g., the bone marrow and the thymus) itself, and the lungs in the form of immune-mediated pneumonitis. (wikipedia.org)
  • Chronic graft-versus-host disease also attacks the above organs, but over its long-term course can also cause damage to the connective tissue and exocrine glands. (wikipedia.org)
  • The chronic form of graft-versus-host disease (cGvHD) normally begins 90 to 600 days post-transplant. (wikipedia.org)
  • The airway inflammation of chronic obstructive pulmonary disease (COPD) is largely neutrophilic, but 20-40% of induced sputum samples from individuals with stable COPD have eosinophilic airway inflammation, associated with elevated levels of sputum interleukin (IL)-5. (medscape.com)
  • Not to be confused with Host-versus-graft disease . (wikipedia.org)
  • Mouse colon impacted by acute graft-versus-host disease. (wikipedia.org)
  • Micrographs of grades of skin graft-versus-host disease: Ranging from grade I GvHR (with minimal vacuolization in the epidermis) to grade II GvHR (with vacuolization and dyskeratotic bodies) to grade III GvHR (with sub epidermal cleft formation) and finally to grade IV GvHR (with separation of the dermis from the epidermis). (wikipedia.org)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is applied successfully to the treatment of many hematopoietic malignancies, but remains limited by severe acute graft-versus-host-disease (aGvHD). (frontiersin.org)
  • Study end points were the probabilities of overall survival, leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM) and chronic graft- versus -host disease. (haematologica.org)
  • Current data suggest that oral lichen planus (OLP) is a T-cell-mediated autoimmune disease in which autocytotoxic CD8 + T cells trigger the apoptosis of oral epithelial cells. (medscape.com)
  • In the evolving landscape of graft-versus-host disease management, staying abreast of current and projected epidemiological trends is vital. (researchandmarkets.com)
  • Developed for decision-makers, this Graft vs. Host Disease - Epidemiology Forecast - 2032 report provides a detailed panorama on the incidence and prevalence of this severe complication of allogeneic stem cell transplantation in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. (researchandmarkets.com)
  • Armed with historical and forecasted data, the report elucidates the severity and organ-specific grading of graft-versus-host disease cases. (researchandmarkets.com)
  • This comprehensive knowledge is paramount for informed decision-making and strategic planning in the quest to tackle graft-versus-host disease. (researchandmarkets.com)
  • Graft-versus-host disease is a potentially serious complication of allogeneic stem cell transplantation. (researchandmarkets.com)
  • Total allogenic transplant cases of graft-versus-host disease in the 7MM range from ~24,440 in 2022 to ~29,600 in 2032. (researchandmarkets.com)
  • Graft-versus-host disease is categorized into two types: acute and chronic graft-versus-host disease. (researchandmarkets.com)
  • In the 7MM, the acute graft-versus-host disease incident cases were ~10,340 in 2022, which are likely to increase to ~12,360 by 2032. (researchandmarkets.com)
  • Furthermore, in the 7MM, the 5-year prevalence of chronic graft-versus-host disease was ~23,080 in 2022, which is likely to increase to ~26,300 cases by 2032. (researchandmarkets.com)
  • An assessment of the degree of involvement of these organs determines the severity of acute graft-versus-host disease. (researchandmarkets.com)
  • The overall severity of chronic graft-versus-host disease is classified as mild, moderate, or severe based on organ-specific grading (number of organs and severity). (researchandmarkets.com)
  • Approximately ~45% of 5-year prevalent cases of chronic graft-versus-host disease belong to the moderate category. (researchandmarkets.com)
  • Skin (~59%), oral mucosa (~53%), eyes (~53%), lungs (~43%), liver (~29%), joints and fascia (~28%), and gastrointestinal (~23%) are the most often affected organs by chronic graft-versus-host disease. (researchandmarkets.com)
  • In 2022, the 7MM mortality-adjusted treated acute graft-versus-host disease patients were ~9,830 in first-line, and these cases are expected to increase to ~11,740 cases by 2032. (researchandmarkets.com)
  • This "Graft vs. Host Disease - Epidemiology Forecast - 2032" report delivers an in-depth understanding of Graft vs. Host Disease, historical and forecasted epidemiology in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. (researchandmarkets.com)
  • the disease is a side effect that is common after an allogeneic bone marrow transplant. (researchandmarkets.com)
  • The two main types of Graft vs. Host Disease are acute Graft vs. Host Disease and Chronic Graft vs. Host Disease. (researchandmarkets.com)
  • As an allogeneic transplant recipient, the patient might experience either form of Graft vs. Host Disease, either form, or neither. (researchandmarkets.com)
  • Chronic graft- versus -host disease (cGvHD) is a major cause of morbidity after hematopoietic stem cell transplantation (HSCT). (haematologica.org)
  • As a result, HSCT is often attributed to an increased risk of health complications, the most severe being chronic graft- versus -host disease (cGvHD). (haematologica.org)
  • The transplantation of stem cells from a healthy donor (allogeneic) offers the chance of cure for patients with an aggressive form of chronic lymphocytic leukemia (CLL), irrespective of genetic prognostic factors and the prior course of the disease. (disabled-world.com)
  • Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X Trial. (disabled-world.com)
  • Defibrotide: Real World Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Stem Cell Transplant. (harvard.edu)
  • Efficacy and Safety of 1% Progesterone Gel to the Forehead for Ocular Chronic Graft-versus-Host Disease. (harvard.edu)
  • Vulvovaginal chronic graft-versus-host disease with allogeneic hematopoietic stem cell transplantation. (soulsource.com)
  • Approximately 30-70% of patients who have undergone allogeneic (allo) hematopoietic stem cell transplantation (HSCT) eventually experience chronic graft-versus-host disease (cGVHD). (biomedcentral.com)
  • Chronic graft-versus-host disease (cGVHD) is a long-term complication of allogeneic hematopoietic stem cell transplantation. (elsevierpure.com)
  • OBJECTIVES: - To investigate efficacy of topical clobetasol 0.05% oral rinse for oral chronic graft versus-host disease (cGVHD) ELIGIBILITY: - Patients age 12-99 years with clinically significant oral cGVHD. (getwellsoon.ai)
  • Chronic ocular graft-versus-host-disease (oGVHD) is an important complication of allogeneic Hematopoietic Stem Cell Transplantation (HSCT). (uillinois.edu)
  • Dr. Jain is a member of the International Chronic Ocular Graft-vs-Host-Disease Consensus Group and an invited member of the International Dry Eye WorkShop (DEWS). (uillinois.edu)
  • Impaired Bone Mineral Density in Pediatric Patients with Chronic Graft-versus-Host Disease. (qxmd.com)
  • Pediatric allogeneic hematopoietic stem cell transplantation (AHSCT) recipients with chronic graft-versus-host disease (cGVHD) are at high risk for endocrinopathies, particularly impaired bone mineral density (BMD). (qxmd.com)
  • We report 33 patients with cGVHD who were referred to the National Institutes of Health (NIH) for the Natural History of Clinical and Biological Factors Determining Outcomes in Chronic Graft-versus-Host Disease Study (NCT 0092235) and underwent formal BMD assessment via dual-energy X-ray absorptiometry (DEXA). (qxmd.com)
  • Advances in the management of chronic kidney disease. (qxmd.com)
  • We use three different medical environments to analyze the mechanisms behind these conditions: systemic sclerosis, pregnancy-related pathologies, and chronic graft versus host disease (cGVHD). (cnrs.fr)
  • ABSTRACT Introduction: The perception of prejudice against, and stigmatization of, sickle cell disease (SCD) leads the patient to perceive a different treatment, due to the disease stigma and maybe related to a worse quality of life (QoL). (scielo.br)
  • Objectives: Describe and evaluate the perception of the prejudice against the disease and its impact on the quality of life of patients with sickle cell disease. (scielo.br)
  • However, in sickle cell disease (SCD) primarily due to repeated blood transfusions and hemolysis-induced recycling of iron, its supplementation during pregnancy remains questionable and may be harmful. (scielo.br)
  • Oral lichen planus (OLP) is a chronic inflammatory disease that causes bilateral white striations, papules, or plaques on the buccal mucosa, tongue, and gingivae. (medscape.com)
  • Humanigen believes that GM-CSF neutralization with lenzilumab also has the potential to reduce the hyper-inflammatory cascade known as cytokine release syndrome common to chimeric antigen receptor T-cell (CAR-T) therapy and acute Graft versus Host Disease (aGvHD). (businesswire.com)
  • BioSenic is currently preparing a fundraising to be organized in Q3/Q4 2023 to initiate the Phase III clinical trial in chronic graft versus host disease (cGVHD) in Q1 2024. (lifecarenews.in)
  • Transplantation-related issues such as graft versus host disease, graft failure, chronic immunosuppressive therapy, and transplantation-related mortality should be carefully considered prior to proceeding with this approach. (medscape.com)
  • Chronic graft vs. host disease and hypogammaglobulinemia predict a lower immunological response to the BNT162b2 mRNA COVID-19 vaccine after allogeneic hematopoietic stem cell transplantation. (cdc.gov)
  • There were no associations with polyomavirus detection pressed persons with AIDS, although clinical consequenc- and acute graft versus host disease, cytomegalovirus re- es of reactivation were not examined ( 17 ). (cdc.gov)
  • Graft-versus-host disease is a potentially serious complication in a recipient of an allograft (usually a haematopoietic stem cell transplant) that arises from the attack of recipient tissues (such as the skin, liver or gut) by donor-derived T cells. (nature.com)
  • establish a convolutional neural network-based model to predict acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation. (nature.com)
  • Unexplained chronic liver disease in Ethiopia: a cross-sectional study. (uib.no)
  • Patients with Treatment-Requiring Chronic Graft versus Host Disease after Allogeneic Stem Cell Transplantation Have Altered Metabolic Profiles due to the Disease and Immunosuppressive Therapy: Potential Implication for Biomarkers. (uib.no)
  • Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex. (unibas.ch)
  • Covariance pattern models were used to determine predictors of regret over time, including baseline characteristics and post-alloHCT outcomes (acute or chronic graft-versus-host-disease, disease recurrence). (cdc.gov)
  • The risk of regretting transplantation was 17.5 percentage points (95% confidence interval, 5.5-29.7 percentage points) greater in patients who developed disease recurrence after HCT compared with patients who did not. (cdc.gov)
  • Graft-versus-host disease and graft-versus-leukemia responses. (medlineplus.gov)
  • This disease is characterized by the malfunctioning of the DNA repair mechanism, which present an increase in the rate of spontaneous damage, among these spontaneous chromosomal instability, and hypersensitivity of cells to the chromosomal breaking effect induced by clastogenic agents 2-3 . (bvsalud.org)
  • The potential role of elastin in patients with myeloid leukemia treated with hematopoietic stem cell transplantation (HSCT) has not been investigated so far. (medscimonit.com)
  • Thus, we studied the safety, efficacy, and feasibility of transfer of gene modified donor T-cells shortly after allo-HSCT in two clinical trials between 2002 and 2007 and here we compare the results to unmodified donor leukocyte infusion (DLI). (frontiersin.org)
  • The aim of these trials was to provide patients with the protection of T-cells after T-cell-depleted allo-HSCT in the matched or mismatched donor setting with an option to delete transduced T-cells, if severe aGvHD occurred within the trial period. (frontiersin.org)
  • Recently, we and others have shown that allogeneic hematopoietic stem cell transplantation (allo-HSCT) may represent a valid treatment option in leukemic myeloid sarcoma. (haematologica.org)
  • Hematopoietic stem cell transplantation (HSCT) is an important therapeutic option for patients with non-malignant diseases as well as high-risk and refractory hematopoietic malignancies. (haematologica.org)
  • 1 HSCT may be followed by chronic inflammation due to tissue self-antigen mismatches among the transplant donor and recipient. (haematologica.org)
  • 3 cGvHD has been estimated to develop in 25% of pediatric and 60% of adult HSCT survivors, may cause chronic and often irreversible organ damage, and has a 10-25% mortality rate. (haematologica.org)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) in thalassemia remains a challenge. (nih.gov)
  • Allogeneic hematopoietic stem cell transplantation (HSCT) offers the only curative modality for many hematological disorders. (hindawi.com)
  • Hematopoietic stem cell transplantation (HSCT) remains an important therapy for long term remission of many malignant and nonmalignant hematological disorders [ 1 , 2 ]. (biomedcentral.com)
  • An estimated 30-70% of allo-HSCT recipients, who survive more than 100 days after transplantation, develop cGVHD. (biomedcentral.com)
  • Allogeneic hematopoietic stem cell transplantation (allo-HSCT) involves the infusion of stem cells following administration of high-dose chemotherapy or total body irradiation for either tumor control or to prevent solid transplant rejection. (gvhdhub.com)
  • Allo-HSCT is an important treatment strategy, which allows administration of myeloablative therapy and the elimination of cancer cells by the transplanted donor T and natural killer (NK) cells in a phenomenon known as the graft- versus -leukemia (GvL) effect. (gvhdhub.com)
  • The Hematopoietic stem cell transplantation (HSCT) is used in children as a definitive treatment for various oncological, immune deficiencies, hemoglobinopathy, and malignancies diseases that involve the hematological system, congenital metabolism disorders, among others. (bvsalud.org)
  • This is a quantitative, retrospective, observational, descriptive and analytical quantitative approach approaching the medical records of children and adolescents submitted to HSCT in a referral hospital service for this type of transplantation in the state of Rio Grande do Sul North (RN). (bvsalud.org)
  • The profile of the clinical variables presented by the children and adolescents of this study shows that the most prevalent diagnosis was ALL, the most frequent toxicities were gastrointestinal, cardiac, respiratory and hematological, the most common HSCT was allogeneic peripheral blood and the greatest cause of mortality was sepsis. (bvsalud.org)
  • Hematopoietic stem cell transplantation not responded to other therapeutic modalities, with (HSCT) is used in children as a definitive treatment an increase in survival after transplantation, for different oncological, immune deficiencies, contributing to its use (YEILIPEK, 2014). (bvsalud.org)
  • For the purposes of this document, HSCT is defined of the CDC, the Infectious Diseases Society of America, as any transplantation of blood or marrow-derived he- and the American Society of Blood and Marrow Trans- matopoietic stem cells, regardless of transplant type plantation," which was published in the Morbidity and (allogeneic or autologous) or cell source (bone marrow, Mortality Weekly Report [1]. (cdc.gov)
  • Opportunistic infections (OIs) are defined as any in- the infusion of hematopoietic stem cells from a donor fections that occur with increased frequency or severity into a patient who has received chemotherapy, which in HSCT patients. (cdc.gov)
  • There pediatric and adult autologous and allogeneic HSCT patients. (cdc.gov)
  • are basically 3 phases of immune recovery for HSCT patients, The purposes of the guidelines are (1) to summarize the beginning at day 0, the day of transplantation. (cdc.gov)
  • In large patient populations, we have shown a CD56 bright natural killer (NK) population to strongly associate with a lack of cGvHD and we hypothesize that these cells function to suppress cGvHD. (haematologica.org)
  • We aimed to isolate and define the characteristics of regulatory NK (NK reg ) cells associated with suppression of cGvHD. (haematologica.org)
  • Moreover, this is the first paper to clearly establish that a CD56 bright CD3 - CD16 - perforin- NK reg population associates with a lack of cGvHD and has several unique characteristics, including the suppression of helper T-cell function in vitro. (haematologica.org)
  • With further investigation we may decipher the mechanism of NK reg suppression and operationalize expansion of NK reg cells associated with cGvHD suppression. (haematologica.org)
  • 2 cGvHD is a multisystemic disorder that occurs due to foreign donor immune cells attacking the recipient's tissues. (haematologica.org)
  • Various immune-suppressive cell populations appear to associate with suppression of cGvHD, including T reg cells, B reg cells, M2 macrophages, dendritic cells, and CD56 bright natural killer (NK) cells. (haematologica.org)
  • The 5-year overall survival and cGVHD recurrence-free survival rates were significantly higher in EW-cGVHD than Dp-cGVHD (96% vs. 68%, p = 0.017 and 84% vs. 41%, p = 0.002, respectively). (elsevierpure.com)
  • They occur on a systemic level in systemic sclerosis, they are localized in pregnancy-related diseases and they are induced by an external graft in cGVHD. (cnrs.fr)
  • The US Food and Drug Administration (FDA) approved omidubicel-onlv (Omisirge) for reducing infections and hastening neutrophil recovery for blood cancer patients aged 12 years and older who are undergoing allogeneic umbilical cord blood stem cell transplants. (medscape.com)
  • The FDA approval was based on phase 3 testing that pitted the use of omidubicel in 62 patients against standard unmanipulated cord blood transplants in 63 patients following myeloablative conditioning. (medscape.com)
  • Overall, 87% of patients who received omidubicel achieved neutrophil recovery, vs 83% of patients with standard transplants. (medscape.com)
  • The FDA's "approval is an important advance in cell therapy treatment in patients with blood cancers. (medscape.com)
  • Abbey Jenkins, president and CEO of Gamida, called the approval "a major advancement in the treatment of patients with hematologic malignancies that we believe may increase access to stem cell transplant and help improve patient outcomes. (medscape.com)
  • Cite this: FDA OKs Stem Cell Therapy to Reduce Infection Risk in Blood Cancer Patients - Medscape - Apr 18, 2023. (medscape.com)
  • CheckMate -67T is a Phase 3 randomized, open-label trial evaluating subcutaneous administration of Opdivo co-formulated with Halozyme's proprietary recombinant human hyaluronidase, rHuPH20, or subcutaneous nivolumab (nivolumab and hyaluronidase) compared to intravenous (IV) Opdivo , in patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who have received prior systemic therapy. (businesswire.com)
  • Donor chimerism was stabilized after transfusion of the transduced cells in all patients treated. (frontiersin.org)
  • To date, six patients have relapsed and died, two after a second hematopoietic stem cell transplantation without T-cell depletion or administration of unmodified T-cells. (frontiersin.org)
  • The role of autoimmunity in the pathogenesis is supported by many autoimmune features of oral lichen planus, including its chronicity, onset in adults, predilection for females, association with other autoimmune diseases, occasional tissue-type associations, depressed immune-suppressor activity in patients with oral lichen planus, and the presence of autocytotoxic T-cell clones in lichen planus lesions. (medscape.com)
  • MRK ), known as MSD outside of the United States and Canada, and Eisai today provided updates on two Phase 3 trials, LEAP-006 and LEAP-008, evaluating KEYTRUDA, Merck's anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in patients with certain types of metastatic non-small cell lung cancer. (streetinsider.com)
  • Objective: to evaluate and correlate the quality of life and financial toxicity of adult patients undergoing hematopoietic stem cell transplantation during the COVID-19 pandemic. (bvsalud.org)
  • Method: observational, analytical study, carried out with 35 patients in a reference hospital for transplantation in Latin America. (bvsalud.org)
  • For conditioning for transplantation, patients were given a reduced dosage of chemotherapy so that the acute tolerance of the transplantation was very good. (disabled-world.com)
  • For a large percentage of patients, highly sensitive tests were conducted regularly to detect any remaining leukemia cells after the transplantation. (disabled-world.com)
  • In about half of these patients, no remaining CLL cells were detected in the blood in the long term, which was highly predictive for the lack of recurrence for the follow-up period (up to eight years, on average about four years). (disabled-world.com)
  • Allogeneic stem cell transplantation is a very stressful and risky form of therapy, which could previously not be carried out on the generally older patients affected by CLL. (disabled-world.com)
  • Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC), regardless of PD-L1 expression levels. (advfn.com)
  • The long-term efficacy seen with the dual immunotherapy regimen in CheckMate -227 reinforce the importance of nivolumab plus ipilimumab to transform outcomes for appropriate patients with metastatic non-small cell lung cancer. (advfn.com)
  • PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced results for the co-primary endpoint for CheckMate -915, a randomized Phase 3 study evaluating Opdivo (nivolumab) plus Yervoy (ipilimumab) versus Opdivo for patients who have had a complete surgical removal of stage IIIb/c/d or stage IV melanoma. (bms.com)
  • On the other hand, bulk RNA-sequence analyses reveal that gene expression profiles among patients are different according to the cytomegalovirus reactivation pattern, and are associated with cytokine production or cell division. (nature.com)
  • We observed that IL-1β-activated microvascular endothelial cells from SSc patients induce monocytes to differentiate into DC-SIGN+-, alternatively activated macrophages producing high levels of CCL18, CCL2 and CXCL8, but no IL-10. (cnrs.fr)
  • In their study of 116 patients (51 males and 65 females) with thalassemia major, males were receiving more units of RBCs per transfusion and had a higher annual transfusion volume, but with correction for weight, females were receiving a higher transfused volume per kg: 225 versus 202 mL/kg in males ( P =0.028). (medscape.com)
  • Allogeneic hematopoietic transplantation may be curative in some patients with thalassemia major. (medscape.com)
  • Defibrotide mitigates endothelial cell injury induced by plasmas from patients with COVID-19 and related vasculopathies. (cdc.gov)
  • Prevalence of decisional regret among patients who underwent allogeneic hematopoietic stem cell transplantation and associations with quality of life and clinical outcomes. (cdc.gov)
  • Conclusions: Among patients who underwent alloHCT and lived to 100 days, the majority did not report regretting their transplantation. (cdc.gov)
  • Bristol Myers Squibb (NYSE: BMY) today announced the Phase 3 CheckMate -77T trial met its primary endpoint of improved event-free survival (EFS) as assessed by Blinded Independent Central Review (BICR) in patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). (santaclara.com)
  • We've seen tremendous scientific advancements in the treatment of non-metastatic non-small cell lung cancer in recent years, and remain committed to researching new solutions that may help even more patients achieve better long-term outcomes," said Abderrahim Oukessou, M.D., vice president, thoracic cancers global program lead, Bristol Myers Squibb. (santaclara.com)
  • CheckMate -77T is a Phase 3 randomized, double-blind, placebo-controlled, multi-center trial evaluating neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo versus neoadjuvant chemotherapy and placebo followed by surgery and adjuvant placebo in 452 patients with resectable stage IIA to IIIB non-small cell lung cancer (NSCLC). (santaclara.com)
  • Dr. Kurtzberg is an internationally renowned expert in pediatric hematology/oncology, pediatric blood and marrow transplantation, umbilical cord blood banking and transplantation, and novel applications of cord blood and birthing tissues in the emerging fields of cellular therapies and regenerative medicine. (duke.edu)
  • Here we show the features of repertoire diversity and the gene expression profile of HLA-A24 cytomegalovirus-specific cytotoxic T-cells in actual recipients according to the cytomegalovirus reactivation pattern. (nature.com)
  • HLA-DP diversity is associated with improved response to SARS-Cov-2 vaccine in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Third Early 'Booster' Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses. (cdc.gov)
  • To validate this PCR, a and WUPyV DNA was developed and used to examine subset of KIPyV-positive, WUPyV-positive, KIPyV-neg- nasal wash specimens collected prospectively from HCT ative, and WUPyV-negative samples was blindly retested recipients with and without respiratory symptoms for 1 by using published assays for detection of KIPyV ( 23 ) and year after transplantation. (cdc.gov)
  • Hopefully, following the recommendations made in the guidelines will reduce morbidity and mortality from opportunistic infections in hematopoietic stem cell transplant recipients. (cdc.gov)
  • Oral lichen planus (OLP) is a chronic mucocutaneous disorder that presents in a wide range of clinical forms, such as unilateral or bilateral white striations, papules, or plaques on the buccal mucosa, labial mucosa, tongue, and gingiva. (medscape.com)
  • The German CLL Study Group proved this in a multi-centric clinical phase II study led by Professor Dr. Peter Dreger, senior consultant and head of the division of stem cell transplantation at the Department of Internal Medicine V at Heidelberg University Hospital. (disabled-world.com)
  • These methods and results can help us to better understand immune reconstitution following hematopoietic cell transplantation, leading to future studies on the clinical application of adoptive T-cell therapies. (nature.com)
  • A better and deeper understanding of immune reconstitution following allo-HCT is required for further clinical application of these adoptive T-cell therapies. (nature.com)
  • BioSenic is a leading biotech company specializing in the development of clinical assets issued from: (i), the allogeneic cell therapy platform ALLOB and (ii) the Arsenic TriOxide (ATO) platform. (lifecarenews.in)
  • CD34-selection of stem cells reduces the risk of aGvHD, but also leads to increased infectious complications and relapse. (frontiersin.org)
  • White blood cells of the donor's immune system which remain within the donated tissue (the graft) recognize the recipient (the host) as foreign (non-self). (wikipedia.org)
  • Improving immune recovery following alternative donor stem cell transplantation using donor graft manipulation. (duke.edu)
  • KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body's immune system to help detect and fight tumor cells. (merck.com)
  • This is a group of rare disorders caused by mutations in different genes involved in the development and function of infection-fighting immune cells. (clevelandclinic.org)
  • It is crucial to control the transplanted donor immune cells so that the effect is strong enough to eliminate the leukemia cells but not strong enough to lead to complications in other tissues and organs. (disabled-world.com)
  • Cytomegalovirus reactivation is still a critical concern following allogeneic hematopoietic cell transplantation, and cellular immune reconstitution of cytomegalovirus-specific cytotoxic T-cells is necessary for the long-term control of cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation. (nature.com)
  • However, cellular immune reconstitution of CMV-specific cytotoxic T-cells (CMV-CTL) is generally considered to be necessary for the long-term control of CMV reactivation after allo-HCT. (nature.com)
  • Our ongoing and future studies aim to characterize immune functions of endothelial cell-induced DC-SIGN+ alternatively activated macrophages and to test whether DC-SIGN targeting could alter these functions both in vitro and in mouse models of SSc. (cnrs.fr)
  • The graft usually comes from a human leukocyte antigen (HLA)-matched donor and contains hematopoietic cells as well as immune cells, including T lymphocytes. (gvhdhub.com)
  • One concern about the procedure is that immune cells in cord blood do not have experience with the viruses responsible for latent infections, leading to a higher percentage of naive T cells and thus increased vulnerability to reactivation of cytomegalovirus or Epstein-Barr virus infection. (msdmanuals.com)
  • The only factor associated with higher non-relapse mortality was patient gender (male: 27±6% vs . female: 10±5%, P =0.04). (haematologica.org)
  • We are ecstatic to see Opdivo plus Yervoy continue to demonstrate almost double the overall survival rates as chemotherapy after six years of follow-up - the longest-ever for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer. (advfn.com)
  • The most common pulmonary complication is pulmonary hypertension from chronic embolization of ova. (medscape.com)
  • Chimeric antigen receptor T-cell therapy has recently emerged as a potent and potentially curative form of immunotherapy in hematological malignancies. (mayoclinic.org)
  • Omidubicel is made from umbilical cord donor stem cells that are processed with nicotinamide, a form of vitamin B3, to enhance and expand the number of progenitor cells, the product's maker, Israel-based Gamida Cell, explained in a press announcement . (medscape.com)
  • BACKGROUND:Umbilical cord blood has become an important source of hematopoietic stem and progenitor cells for therapeutic applications. (duke.edu)
  • This article contains highlights of "Guidelines for Pre- allogeneic or autologous, depending on the source of venting Opportunistic Infections among Hematopoi- the transplanted hematopoietic progenitor cells. (cdc.gov)
  • Renal cell carcinoma (RCC) is the most common type of kidney cancer in adults, accounting for more than 431,000 new cases and 179,000 deaths worldwide each year. (businesswire.com)
  • Clear cell renal carcinoma (ccRCC) is the most common form of RCC, affecting about 7 out of 10 people with RCC. (businesswire.com)
  • KEYTRUDA plus LENVIMA is approved in the U.S., the EU, Japan and other countries for the treatment of advanced renal cell carcinoma (RCC) and certain types of advanced endometrial carcinoma. (streetinsider.com)
  • Imoxin attenuates high fructose induced oxidative stress and apoptosis in renal epithelial cell via downregulation of PKR Pathway. (uib.no)
  • The dense subepithelial mononuclear infiltrate in oral lichen planus is composed of T cells and macrophages, and there are increased numbers of intraepithelial T cells. (medscape.com)
  • Besides the secretion of pro-inflammatory cytokines (TNF-alpha, IL-1beta, and IL-6), the increased expression of receptor repertoire (pattern recognition receptors, PRR) on APCs, mostly macrophages and dendritic cells, occurs as a result of the release of endogenous and exogenous antigens (damage-associated molecular patterns, DAMPs, and pathogen-associated molecular patterns, PAMPs). (hindawi.com)
  • The main risk still remains the "graft-versus-host reaction", in which donor cells attack the patient's own cells, which are foreign to them. (disabled-world.com)
  • Hematopoietic stem cell transplantation may be autologous (using the patient's own cells) or allogeneic (using cells from a donor). (msdmanuals.com)
  • Randomization was stratified by tumor histology (squamous cell carcinoma vs. adenocarcinoma), geographic region (Asia vs. ex-Asia), and Eastern Cooperative Oncology Group (ECOG) performance status (PS) (0 vs. 1). (merck.com)
  • pulmonary histiocytosis X or Langerhans cell granulomatosis). (medscape.com)
  • Papillary atrophy, macroglossia, melanic pigmentation and squamous cell carcinoma are the most common oral manifestations on the tongue. (bvsalud.org)
  • Squamous cell carcinoma. (bvsalud.org)
  • Conclusion: The current study shows iron sufficiency in most cases of pregnancy with SCA and suggests that evaluation of iron status must be made before initiating iron prophylaxis in pregnant women with SCA, especially in regions having a high prevalence of sickle cell hemoglobinopathy. (scielo.br)
  • COVID-19 Infection in a Child With Thalassemia Major After Hematopoietic Stem Cell Transplant. (cdc.gov)
  • Successful treatment of therapy-resistant chronic leukemia using allogeneic stem cell transplantation. (disabled-world.com)
  • Our study is the largest so far for this patient population and proved that allogeneic stem cell transplantation is a promising therapy option for high-risk CLL and has the potential to cure for this otherwise incurable kind of leukemia," says Professor Dreger, head of the study. (disabled-world.com)
  • The merger also enables Biosenic to add to its innovative cell therapy platform and strong IP for tissue repair protection with an entirely new arsenal of various anti-inflammatory and anti-autoimmune formulations using the immunomodulatory properties of ATO/OATO. (lifecarenews.in)
  • Double allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies. (unibas.ch)
  • Its current investigational medicinal product, ALLOB, represents a unique, proprietary approach to organ repair and specifically to bone regeneration, by turning undifferentiated stromal cells from healthy donors into bone-forming cells on the site of injury after a single local injection. (lifecarenews.in)
  • Hämostaseologie : Organ der Gesellschaft für Thrombose- und Hämostaseforschung e.V. (GTH), Vol. 29. (unibas.ch)
  • Vascular endothelial cells form the interface between recipient tissues and circulating alloreactive donor T cells after allogeneic stem cell transplantation. (nih.gov)
  • Donor-T-cells were transduced with the replication-deficient retrovirus SFCMM-3, expressing HSV-TK and the truncated ΔLNGFR for selection of transduced cells. (frontiersin.org)
  • Before a transplant, tissue and cells from possible donors are checked to see how closely they match the recipient. (medlineplus.gov)
  • Host endothelial cells are a target of alloreactive donor cytotoxic T lymphocytes. (nih.gov)